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A B S T R A C T
Type 2 diabetes mellitus (T2DM) is an important public health worldwide. The main underlying mechanism of
T2DM is insulin resistance which is associated with chronic inﬂammation. Interleukin-32 (IL-32) is a pro-in-
ﬂammatory cytokine which has been implicated in pro-inﬂammatory responses of several human diseases.
Previous studies have reported higher levels of IL-32 in inﬂammatory disease and obesity. The present study
aimed to evaluate the serum concentrations of IL-32 in patients with T2DM and its association with cardio-
metabolic parameters.
This study was undertaken on 93 patients with TDM and 74 healthy controls. T2DM was diagnosed based on
ADA criteria. Serum levels of IL-32, adiponectin, TNF-α, and IL-6 were measured by ELISA technique.
Our ﬁndings revealed independent elevated levels of IL-32 in T2DM group (1061 (841.9–1601) pg/mL)
compared to the control (630.4 (331.1–830.9) pg/mL). Furthermore, it was associated with increased risk of
T2DM incidence. IL-32 indicated a positive correlation with body mass index, fasting blood glucose, TNF-α, and
IL-6 in patients with T2DM. Furthermore, linear regression showed independent association between IL-32 and
IL-6 plus TNF-α in patients’ group.
The results of the present study revealed higher levels of IL-32 in T2DM patients which have been associated
with inﬂammatory markers. These results suggest the possible role of IL-32 in chronic inﬂammation in patients
with T2DM.
1. Introduction
The prevalence of T2DM is rapidly increasing worldwide, which has
become a major public health problem [1]. Over-nutrition, inactivity,
and obesity are important risk factors for T2DM development [2]. This
disease has grave consequences such as atherosclerosis, neuropathy,
nephropathy, and retinopathy which lead to high morbidity and mor-
tality [3].
Lipotoxicity, oxidative stress, ER stress, and inﬂammation play an
important role in the development of insulin resistance [4]. Cross-sec-
tional and prospective studies have reported perturbation of in-
ﬂammatory markers in the context of T2DM [5]. For instance, several
lines of evidence have indicated the role of cytokines including tumor
necrosis factor alpha (TNF-α), interleukin (IL)-1b, IL-6, IL-18, and
interferon-gamma in the pathogenesis of atherosclerosis [5–7].
IL-32, also called natural killer cell transcript-4 and TNF-α-induced
factor, is a novel pro-inﬂammatory cytokine which has important
functions in immune regulation [8]. It can provoke inﬂammation by
evoking other cytokines including TNF-α, IL-1b, IL-6, and IL-8 [8,9]. It
has been demonstrated that IL-32 is expressed in human peripheral
blood mononuclear cells and its expression is regulated by in-
ﬂammatory cytokines [10]. Therefore, it has been speculated that IL-32
is involved in inﬂammatory diseases [10,11]. Previous studies have
reported the important role of IL-32 in human inﬂammatory diseases
such as Crohn’s disease, ulcerative colitis, and rheumatoid arthritis
[12,13]. It has been found that IL-32 overexpression in high fat diet
mice protects them from hepatic inﬂammation and steatosis [14].
However, it has been reported that IL-32 overexpression in
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streptozotocin (STZ)-induced diabetic mice involved in pancreatic in-
ﬂammation and β-cell injuries [15]. Catalan et al. showed that IL-32
knockdown in human adipocyte decreased the expression of
inﬂammatory genes [16]. Furthermore, they reported higher adipose
tissue mRNA expression and circulating levels of IL-32 in obese patients
and obese T2DM patients compared to lean normal group [16].
Accordingly, the purpose of this study was to evaluate the serum
levels of IL-32 in T2DM and controls which were matched in terms of
BMI and age. Also, the relationship between IL-32 and anthropometrics
as well as biochemical and inﬂammatory cytokines was tested in the
groups.
2. Study population and methods
2.1. Participants
This case control study enrolled 93 patients with T2DM and 74
healthy individuals between the ages of 55 and 75 years who presented
for routine check-up in Hajar Hospital between Jun 2017 and December
2018. T2DM was diagnosed based on ADA criteria [17]. Individuals
with a history of any inﬂammatory diseases including rheumatoid ar-
thritis, severe kidney and liver diseases, cancer, infectious disease,
stroke, and heart attack were excluded from the study. All participants
provided written informed consent to participate in this study, and the
Table 1
Anthropometric and biochemical characteristics of studied population.
Variables Control T2DM p
Age (year) 56.99 ± 8.83 58.66 ± 8.42 0.215
BMI (kg/m2) 25.65 ± 3.42 26.41 ± 4.15 0.197
Sex [male (%)] 53 (71.6) 61 (65.6) 0.406
SBP (mmHg) 128.26 ± 16.53 136.60 ± 19.36 0.003
DBP (mmHg) 79 (72.25–86.75) 80 (76–92) 0.007
FBG (mg/dL) 92.35 ± 11.45 164.47 ± 24.37 < 0.001
Insulin (μU/mL) 3.2 (2.05–5.72) 11.6 (9.25–14.6) < 0.001
HOMA-IR 0.73 (0.43–1.24) 4.66 (3.38–6.41) < 0.001
TG (mg/dL) 120.11 ± 44.80 162.44 ± 55.85 < 0.001
TC (mg/dL) 169.57 ± 37.61 191.99 ± 45.98 0.001
LDL-C (mg/dL) 102.53 ± 30.32 119.22 ± 37.01 0.002
HDL-C (mg/dL) 47.19 ± 6.94 42.80 ± 5.38 < 0.001
Creatinine (mg/dL) 1.13 ± 0.18 1.17 ± 0.15 0.070
AST (U/L) 17.83 ± 5.35 19.52 ± 5.84 0.056
ALT (U/L) 17.96 ± 7.55 20.17 ± 7.83 0.067
Adiponectin (µg/mL) 11.90 ± 3.67 9.53 ± 2.56 < 0.001
TNF-α (pg/mL) 21.23 (12.78–26.44) 27.58 (24.05–33.99) < 0.001
IL-6 (pg/mL) 5.23 (4.04–6.21) 9.27 (7.2–12.53) < 0.001
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; FBG, fasting blood glucose; HOMA-IR, homeostatic model assessment
of insulin resistance; TG, triglyceride; TC, total cholesterol; LDL-C, Low density
lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; AST, as-
partate amino transferase; ALT, alanine amino transferase; TNF-α, tumor ne-
crosis factor-α; IL-6, interleukin-6.
Fig. 1. Serum levels of (a) adiponectin, (b) IL-6, (c) TNF-α and (d) IL-32 in the studied groups.
Table 2
Odd ratio for T2DM present according to 10 units change in IL-32 serum levels.
Model Odd ratio (95% conﬁdence interval) p
Crude model 1.049 (1.032–1.066) <0.001
Adjusted model* 1.050 (1.032–1.069) <0.001
* Adjusted for age, sex, BMI and medication
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study was conﬁrmed by the Ethic Committee of Sahrekord University of
Medical Sciences.
2.2. Anthropometric and laboratory evaluation
All the subjects underwent comprehensive physical examinations as
well as biochemical analyses of blood. Body mass index (BMI) was
calculated as weight/height2 (kg/m2). Resting blood pressure was
measured according to the standardized protocol. Blood samples were
collected after a 12-h overnight fasting. Serum samples were stored
at−80 °C until subsequent analyses. Fasting blood glucose (FBG), total
cholesterol (TC), triglycerides (TG) and high density lipoprotein cho-
lesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), alanine
amino transferase (ALT), aspartate amino transferase (AST), and crea-
tinine (Cr) were determined by enzymatic methods using Hitachi au-
toanalyzer. Fasting insulin was measured by ELISA kit (Monobind;
USA) and the standard formula ([fasting blood glucose (mg/
dl)]× [fasting blood insulin (μU/mL)/405]) was applied to calculate
the homeostasis model assessment of insulin resistance (HOMA-IR).
2.3. Measurement of serum adiponectin and cytokines
Serum level of IL-32 was determined using an ELISA kit (R&D
Systems; USA) with intra-assay Coeﬃcients of Variability (CV) < 10%
and Inter-assay CV < 8%. Also, the serum level of adiponectin was
measured using an ELISA kit (Adipogen; South Korea) with intra- and
inter-assay CV of 4.6% and 4.4%, respectively. IL-6 and TNF-α were
Fig. 2. (a) Serum levels of IL-32 in male group compared with female group. (b) Serum levels of IL-32 in smokers compared to non-smokers. (c) IL-32 serum levels in
T2DM patients according to receiving OHA. (d) Serum levels of IL-32 in T2DM patients according to receiving statins.
Fig. 3. ROC curve for diﬀerentiation between T2DM patients and controls ac-
cording to serum levels of IL-32 (Area under curve (95% conﬁdence in-
terval)= 0.859 (0.805–0.913), p < 0.001).
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measured using ELISA kits (R&D Systems; USA). Minimum detectable
doses of IL-6 and TNF-α were 0.7 and 1.6 pg/mL, respectively.
2.4. Statistical analyses
Statistical analyses were performed using SPSS Statistics 17 for
Windows (SPSS Inc., Chicago, IL, USA). Categorical data were tested by
Chi-square test and presented by frequency and percentage. Data were
checked for normality by Kolmogorov–Smirnov test prior to all statis-
tical analyses. Descriptive statistics for normally distributed variables
are expressed as mean ± standard deviation (SD), while non-normally
distributed data are shown by mean and inter quartile range (IQR).
Student’s t test and Man-Whitney test were used to determine diﬀer-
ences in subjects’ characteristics and measured outcomes. Non-normal
data were logarithmically transformed for correlation analysis.
Spearman’ correlation coeﬃcients were computed for the relationship
between IL-32 and all variables. Multiple linear regression was per-
formed to check the correlated parameters with IL-32. Finally, logistic
regression was conducted to evaluate the risk of T2DM according to IL-
32 levels.
3. Results
3.1. Anthropometric and biochemical measurements
Demographic and clinical characteristics of the study participants
are presented in Table 1. Mean age, sex, and BMI of the participants
were not signiﬁcantly diﬀerent. Systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) were higher in T2DM patients compared to
controls. All parameters of glucose metabolism including FBG, insulin,
and HOMA-IR were elevated in T2DM patients compared to controls. In
addition, TG, TC, and LDL-C showed a higher concentration in T2DM
patients compared to controls, while HDL-C was lower in the patient
group. Markers of kidney and liver function including Cr, ALT, and AST
showed no signiﬁcant diﬀerence between the groups. Meanwhile, the
number of smokers was higher in T2DM groups compared to controls.
Finally, 13 patients used OHAs and 10 patients were under statins
therapy.
3.2. Adiponectin and cytokines levels
Our ﬁndings showed that adiponectin level was signiﬁcantly lower
T2DM group than in the control group (Fig. 1a). However, IL-6 and
TNF-α were elevated in patients compared to controls (Fig. 1b and c).
IL-32 serum levels indicated higher levels in patients with T2DM
(1061 (841.9–1601) pg/mL) compared with controls (630.4
(331.1–830.9) pg/mL), (mean and SD in T2DM vs. controls respec-
tively, (1248 ± 551.4 vs 598.4 ± 290.1 pg/mL) (Fig. 1d). In addition,
the eﬀects of possible covariates (age, sex, BMI and medications) were
adjusted on IL-32 serum levels, where the diﬀerence between T2DM
and control groups remained signiﬁcant (p < 0.001). Furthermore,
logistic regression indicated an independent association between IL-32
and incidence of T2DM. Note that the eﬀects of covariates were ad-
justed on the model and the results remained signiﬁcant (Table 2).
The potential of IL-32 for diagnosis of T2DM was tested using ROC
curve analysis. The result indicated a relatively good ability for dif-
ferentiation between disease status and controls using IL-32 (Area
under curve (95% conﬁdence interval)= 0.859 (0.805–0.913),
p < 0.001) (Fig. 3).
3.3. Relation of IL-32, TNF-α and IL-6 with anthropometric as well as
biochemical measurements
IL-32 showed no signiﬁcant diﬀerence between male and female
(Fig. 2a), and smoker and non-smoker (Fig. 2b). Meanwhile, statins and
OHA therapies had no eﬀect on IL-32 serum levels in patients with
Table 3
Correlation and association of log IL-32 with continuous variables.
Variables Control T2DM
Pearson r B (95% CI) Pearson r B (95% CI)
Age −0.221 −0.089
BMI 0.159 0.254* 0.008
(0.000–0.016)
SBP −0.266* −0.004
(−0.008–0.000)*
0.103
Log DBP −0.108 0.105
FBG 0.181 0.204* 0.001
(0.000–0.003)
Log Insulin 0.063 0.096
Log HOMA-IR 0.092 0.152
TG −0.075 −0.060
TC −0.052 0.052
LDL-C −0.053 0.057
HDL-C 0.087 −0.104
Adiponectin 0.111 −0.125
Creatinine 0.278* 0.387
(0.042–0.733)*
−0.026
AST 0.009 −0.182
ALT 0.076 0.009
Log TNF 0.101 0.409** 0.403
(0.144–0.661)**
Log IL-6 0.159 0.405** 0.278
(0.089–466)**
*p < 0.05.
*p < 0.01.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; FBG, fasting blood glucose; HOMA-IR, homeostatic model assessment
of insulin resistance; TG, triglyceride; TC, total cholesterol; LDL-C, Low density
lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; AST, as-
partate amino transferase; ALT, alanine amino transferase; TNF-α, tumor ne-
crosis factor-α; IL-6, interleukin-6.
Table 4
Spearman correlation of TNF-α and IL-6 with continuous variables.
Variables Control T2DM
Log TNF Log IL-6 Log TNF Log IL-6
Log IL-6 0.104 1 0.342** 1
Age 0.056 −0.192 −0.008 0.013
BMI −0.129 0.136 0.018 0.174
SBP −0.177 −0.372** 0.015 0.129
Log DBP −0.105 −0.168 0.053 0.047
FBG −0.089 0.167 0.096 −0.045
Log Insulin −0.106 0.237* 0.086 0.108
Log HOMA-IR −0.112 0.246* 0.115 0.083
TG −0.019 0.002 0.086 0.077
TC 0.071 0.020 0.100 −0.039
LDL-C 0.039 0.040 0.050 −0.069
HDL-C 0.134 −0.056 −0.010 −0.181
Adiponectin −0.025 −0.007 −0.179 −0.237*
Creatinine 0.159 0.094 0.059 −0.192
AST −0.037 −0.029 −0.144 −0.049
ALT 0.020 −0.065 −0.023 0.079
*p < 0.05.
*p < 0.01.
TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; BMI, body mass index; SBP,
systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glu-
cose; HOMA-IR, homeostatic model assessment of insulin resistance; TG, tri-
glyceride; TC, total cholesterol; LDL-C, Low density lipoprotein-cholesterol;
HDL-C, high density lipoprotein-cholesterol; AST, aspartate amino transferase;
ALT, alanine amino transferase.
R. Fadaei, et al. Cytokine 125 (2020) 154832
4
T2DM (Fig. 2c and d). Correlation analysis revealed that IL-32 inversely
correlated with SBP and positively correlated with Cr in control group,
and multiple linear regression indicated independent association of IL-
32 with SBP and Cr in control group (Table 3). Furthermore, IL-32
positively correlated with BMI, FBG, TNF-α, and IL-6 in T2DM group.
Finally, linear regression demonstrated an independent association
between IL-32 and TNF-α as well as IL-6 (Table 3).
TNF-α showed no signiﬁcant correlation with continuous variables
in controls, while IL-6 indicated inverse correlation with SBP and po-
sitive correlation with insulin and HOMA-IR. In addition, IL-6 demon-
strated positive correlation with TNF-α and inverse correlation with
adiponectin in T2DM group (Table 4).
4. Discussion
The relationship between inﬂammation and diabetes mellitus and
insulin resistance is a matter of ongoing research [18]. It has been
suggested that malfunctioning occurs through inﬂammation in insulin
resistance and β-cell function [18]. It has been shown that levels of
inﬂammatory markers such as IL-6, TNF-α, IL-1β, and CRP rise in pa-
tients with T2DM and targeting inﬂammation has been suggested as a
possible therapeutic option for T2DM and its complication such as
atherosclerosis, neuropathy, nephropathy, and retinopathy [19,20].
IL-32 is a cytokine involved in inﬂammation regulation [20–22]. It
has been found that inﬂammation induced by ionizing radiation in-
creased the expression of IL-32 in vascular cells [23]. Indeed, IL-32 can
amplify the inﬂammation upon ionizing radiation [23]. Another study
reported up-regulation of IL-32 in arterial specimens of atherosclerotic
patients [11]. Previous studies on patients with inﬂammatory disease
such as rheumatoid arthritis, Bechet’s diseases, and IBD demonstrated
higher levels of IL-32 in these patients [10,24,25]. Furthermore, a study
by Catalan et Al. reported higher levels of IL-32 in obese and T2DM
obese patients compared to controls [16]. In line with these results, in
the present study IL-32 indicated a higher concentration in T2DM pa-
tients compared to controls, with higher IL-32 concentration being as-
sociated with risk of T2DM incidence. Furthermore, our results showed
that the association between IL-32 serum levels and T2DM was in-
dependent of covariates. In Catalan et al.’s study [16], the patients were
obese while the controls were lean. In the present study, groups were
matched in terms of BMI and we showed that increased IL-32 in T2DM
patients was independent of BMI. However, IL-32 was positively cor-
related with BMI in T2DM patients. Catalan et al. reported elevated IL-
32 expression in adipose tissue of obese subjects and they found a po-
sitive association between IL-32 and BMI [16].
A study found that IL-32 overexpression exacerbates β-cell injuries
and inﬂammation of pancreas in STZ-induced T1DM mice [15]. In the
present study, IL-32 showed a weak positive correlation with FBG and
no correlation with insulin or HOMA-IR in the patient group. In addi-
tion, serum levels of IL-32 showed no signiﬁcant diﬀerence between 13
T2DM patients who received OHA compared with newly diagnosed
patients. Based on these results, IL-32 seems to have a weak association
with glucose metabolism. Note that this study has had a cross-sectional
design and could not conclude a causal relationship; therefore more
studies are needed to evaluate the eﬀects of IL-32 on glucose and insulin
metabolism. IL-32 exhibited a positive correlation with SBP and Cr in
controls. Previous studies have reported increased levels of IL-32 in
response to hypoxia [26], though its relationship with blood pressure
and kidney function is not clear and more studies are warranted in this
regard.
It has been reported that IL-32 aﬀects the inﬂammatory reactions
and promotes production of inﬂammatory cytokines such as TNF-α, IL-
6, IL-1β, and IL-8 [8,27]. In addition, IL-32 accelerates monocyte to
macrophage diﬀerentiation [28]. Further, LPS and TNF-α elevate IL-32
expression while IL-13 decreases its expression [27]. In this regard, IL-
32 levels in synovial biopsies of patients with rheumatoid arthritis re-
vealed a positive association with severity of inﬂammation [29]. In the
present study, IL-32 was found to be correlated with inﬂammatory
cytokines (IL-6 and TNF-α); however, IL-32 demonstrated no correla-
tion with inﬂammatory cytokines in controls. These results suggested a
pro-inﬂammatory role for IL-32 in T2DM where increased inﬂammation
in T2DM could be partially related to increased IL-32 levels.
Six diﬀerent isoforms of IL-32 have been identiﬁed (α, β, γ, δ, ε and
ζ) [30] and the ELISA kit in the present study measured three isoforms,
α, β and γ. IL-32α and IL-32β are suggested to be the major expressed
isoforms and IL-32γ introduced as the most active form [31]. A lim-
itation of the present study was that each isoform was not measured
speciﬁcally, and further studies needed to establish the role of each
isoform in the pathogenesis of insulin resistance and T2DM.
In conclusion, IL-32 increased in T2DM patients and it showed a
positive association with inﬂammatory cytokines in these patients.
These results suggested involvement of IL-32 in chronic inﬂammation
in the context of T2DM. Nevertheless, further studies are required to
evaluate the possible causal relationship between IL-32 and pathogen-
esis of T2DM.
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